FOR LABORATORY RESEARCH USE ONLY · NOT FOR HUMAN CONSUMPTION
◀ INDEXWEIGHT LOSS

PEPTIDES FOR WEIGHT LOSS

RESEARCH REFERENCE · INCRETIN AXIS · GLP-1 · GIP · GLUCAGON

Eight research peptides studied for body composition and glycemic control. The largest weight-loss effects in published trials come from the incretin axis: GLP-1 receptor (the long-acting GLP-1 agonist, the daily GLP-1 agonist), dual GLP-1 plus GIP (the GLP-1 / GIP dual agonist), triple GLP-1 plus GIP plus glucagon (the triple-receptor incretin agonist, the GLP-1 / glucagon dual agonist), and amylin-receptor co-agonists (the amylin receptor agonist). MOTS-c sits outside the incretin family · a mitochondrial-derived peptide studied for metabolic effects. AOD-9604 is a synthetic C-terminal fragment of human growth hormone studied for lipolytic activity.

WHAT THE RESEARCH SHOWS

Incretin receptor agonism drives glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite suppression. Adding the GIP arm (the GLP-1 / GIP dual agonist, the triple-receptor incretin agonist) increases absolute weight loss versus single-agonist GLP-1 compounds. Adding the glucagon arm (the triple-receptor incretin agonist, the GLP-1 / glucagon dual agonist, the GLP-1 / glucagon dual agonist (β)) further increases energy expenditure via thermogenic signaling, which is the leading hypothesis for why the triple-receptor incretin agonist Phase 2 produced deeper body-weight reductions than dual-agonist trials at comparable timepoints.

COMPOUND CLUSTER · 8 ENTRIES

TRI-RECEPTOR INCRETIN AGONIST molecular structure
No. 001
TRI-RECEPTOR INCRETIN AGONIST
METABOLICINCRETIN
GLP-1 / GIP DUAL AGONIST molecular structure
No. 002
GLP-1 / GIP DUAL AGONIST
METABOLICINCRETIN
AMYLIN RECEPTOR AGONIST molecular structure
No. 018
AMYLIN RECEPTOR AGONIST
METABOLIC
GLP-1 / GLUCAGON DUAL AGONIST molecular structure
No. 019
GLP-1 / GLUCAGON DUAL AGONIST
INCRETINMETABOLIC
ORAL GLP-1 RECEPTOR MIMETIC molecular structure
No. 020
ORAL GLP-1 RECEPTOR MIMETIC
INCRETIN
MAZDUTIDE molecular structure
No. 021
MAZDUTIDE
INCRETINMETABOLIC
GH FRAGMENT (LIPOLYTIC) molecular structure
No. 024
GH FRAGMENT (LIPOLYTIC)
METABOLICGROWTH
MOTS-c molecular structure
No. 010
MOTS-c
METABOLICLONGEVITY

RECEPTOR AGONISM MATRIX

COMPOUND
GLP-1
GIP
GCGR
OTHER
tri-receptor-incretin-agonist
yes
yes
yes
·
glp1-gip-dual-agonist
yes
yes
·
·
glp1-glucagon-dual-agonist
yes
·
yes
·
glp1-glucagon-dual-agonist-b
yes
·
yes
·
amylin-receptor-agonist
·
·
·
amylin
oral-glp1-receptor-mimetic
yes (oral, small molecule)
·
·
·
MOTS-c
·
·
·
mitochondrial
AOD-9604
·
·
·
GH C-terminal fragment

FAQ

What peptide has the most weight loss in clinical trials?

the triple-receptor incretin agonist leads published trial data. The Phase 2 NEJM trial (Jastreboff 2023, PMID 37366315) reported -24.2% LS mean body weight at the 12 mg dose arm at 48 weeks. the GLP-1 / GIP dual agonist at 15 mg in SURMOUNT-1 reached -22.5% at 72 weeks. the long-acting GLP-1 agonist 2.4 mg in STEP-1 reached -14.9% at 68 weeks. the triple-receptor incretin agonist is investigational. the GLP-1 / GIP dual agonist is FDA-approved as separate FDA-approved class members. the long-acting GLP-1 agonist is FDA-approved as an FDA-approved class member.

Are research peptides for weight loss FDA approved?

Some incretin agonists are FDA approved as prescription drugs. the GLP-1 / GIP dual agonist (separate FDA-approved class members), the long-acting GLP-1 agonist (separate FDA-approved class members), and the daily GLP-1 agonist (the FDA-approved class member) are FDA approved. the triple-receptor incretin agonist, the GLP-1 / glucagon dual agonist, the oral GLP-1 receptor mimetic, the GLP-1 / glucagon dual agonist (β) and the amylin receptor agonist are investigational. Research-grade material sold as a reference compound is for in-vitro laboratory use only, distinct from any branded prescription product.

the triple-receptor incretin agonist vs the GLP-1 / GIP dual agonist for weight loss?

the triple-receptor incretin agonist is a triple GLP-1 plus GIP plus glucagon agonist. the GLP-1 / GIP dual agonist is a dual GLP-1 plus GIP agonist. The added glucagon arm in the triple-receptor incretin agonist drives a thermogenic / energy-expenditure component on top of the appetite and insulin effects. Phase 2 the triple-receptor incretin agonist produced -24.2% body-weight reduction at 48 weeks vs the GLP-1 / GIP dual agonist -22.5% at 72 weeks. See the full /vs/the triple-receptor incretin agonist-vs-the GLP-1 / GIP dual agonist comparison.

How are these used in research?

All compounds on this page are supplied as research-grade chemical reference material for in-vitro laboratory studies. Each compound page documents the published trial dosing schedule, half-life, mechanism, and per-receptor pharmacology. GigaResearch does not recommend any human dose. For purchase of research-grade material see gigacompounds.com.

RELATED

SOURCED FROM GIGACOMPOUNDS

Research-grade reference compounds available at GigaCompounds · ≥99% purity · per-batch CoA. For laboratory research use only.

SOURCE AT GIGACOMPOUNDS ▶
© 2026 GigaCompounds LLC · For Laboratory Research Use Only